Reuters logo
BRIEF-Omeros to present results from dose-ranging stage of OMS721 Clinical Trial
March 27, 2017 / 11:25 AM / 6 months ago

BRIEF-Omeros to present results from dose-ranging stage of OMS721 Clinical Trial

March 27 (Reuters) - Omeros Corp

* Omeros to present results from dose-ranging stage of oms721 clinical trial in atypical hemolytic uremic syndrome at world congress of nephrology

* Omeros to present results from dose-ranging stage of oms721 clinical trial in atypical hemolytic uremic syndrome at world congress of nephrology

* Omeros corp - mean change from baseline in platelet count was statistically significant as measured by area under curve

* Omeros- renal replacement therapy able to be discontinued in 1 patient during oms721 treatment, renal function remained stable following completion of treatment Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below